Bear posted the other day about some hopeful evidence for ZEN3365 which to me indicated that the Zenith portfolio is not just limited to ZEN3694. Great news. There must be huge potential hidden away there.

I was looking at my investment account today and seeing RVX at $0.64 (a publicly traded company on TSX with FDA BTD) and Zenith at $0.36 (a public company traded only on the OTC markets) and it struck me that  there could not be a more clear display of management incompetence than those numbers reveal.

Then compare these numbers to Repare Therapeutics of Montreal which was founded 5 years ago, listed on NASDAQ at $20 and now trades $33 and their drug development is years behind RVX and Zenith and I got a sinking feeling.

In this light the RVX/ZEN situation is truly pathetic.

I've lost hope for the time being because I have not seen any evidence of the drive and sense of urgency from management. I've not seen any evidence of a competent business skill set. I've not seen evidence of strategic skills on the financing side. Everything seems to be hit and miss.

And now, with Don not answering questions and stretching the "Forward Looking Statements" to the point of lying, it has become somewhat shady. The business side does not seem to be normal for 2 companies that are advancing breakthrough science and developing very strong clinical evidence for both safety and efficacy.

I'll leave it at that. I really appreciate hearing about the wonderful science but it is so sad and regretable that the business side is not competent enough to do their part of the job. In my opinion it would be a true shame to see these 2 gems lost to a competent (possibly foreign - not that it really matters) competitor.

GLTA

Toinv